Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with previously untreated, advanced stage (stage 3 – 4) follicular lymphoma (FL). This study concluded that this regimen was similarly effective as rituximab plus chemotherapy, but had different side effects.

Some background

Chemoimmunotherapy containing rituximab remains the standard first-line (primary) treatment for patients with FL. However, this treatment is associated with side effects. Common side effects include immunosuppression (reduction of the activation or effectiveness of the immune system), heart-related side effects, and neuropathy (numbness or tingling in the hands and feet).

Lenalidomide is an immunomodulatory drug. This type of treatment boosts the body’s immune system to help it attack cancer cells. This leads to cancer cell death. The safety and effectiveness of lenalidomide combined with rituximab versus chemoimmunotherapy in patients with advanced-stage FL remain under investigation.

Methods & findings

This study involved 1030 patients with previously untreated, advanced stage FL. Patients received either rituximab plus lenalidomide (RL; 49.8%) or rituximab plus chemotherapy (RC; 50.2%). After treatment, patients received maintenance therapy (treatment to prevent relapse) with rituximab. Patients were followed-up for an average of 37.9 months.

Overall, 84% (RL) and 89% (RC) of patients responded to treatment. 59% (RL) and 67% (RC) of patients achieved a complete response (disappearance of all signs of cancer).

3-year progression-free survival (patients still alive 3 years later without tumor growth or spread) was similar (77% – RL and 78% – RC%). The probability of a complete response lasting for at least 3 years was 77% in the RL group and 81% in the RC group.

Overall, 99.8% (RL) and 99.0% (RC) of patients reported side effects. The most common ones included low red blood cell count (66% vs. 89%), fatigue (23% vs. 26%), and nausea (20% vs. 42%). Skin reactions (43% vs. 24%), diarrhea (37% vs. 19%), and rash (29% vs. 8%) were also common.

The bottom line

This study concluded that rituximab plus lenalidomide was similarly effective as rituximab plus chemotherapy, but had different side effects in previously untreated patients with FL.

The fine print

This study had a rather short follow-up period. Longer studies are needed to evaluate the long-term effects of this treatment.

Published By :

The New England Journal of Medicine

Date :

Sep 06, 2018

Original Title :

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

click here to get personalized updates